No Data
No Data
No Data
No Data
No Data
Ensysce Biosciences' Presentation From the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published
Noble Capital Markets ("Noble") is a research-driven investment bank that has supported small and microcap companies since 1984.
AccesswireApr 19 20:01
Ensysce Biosciences Reports Q4 Results
Seeking AlphaMar 15 22:26
Ensysce Biosciences Q4 EPS $(1.13) Misses $(0.87) Estimate, Sales $515.03K Beat $390.00K Estimate
Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(1.13) per share which missed the analyst consensus estimate of $(0.87) by 29.89 percent. This is a 93.8 percent increase over losses of
BenzingaMar 15 20:06
Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results
Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today reported financial results for the fourth quarter and full year of 2023.
AccesswireMar 15 20:02
Ensysce Biosciences Announces The Co May Continue Its Listing On The Nasdaq Capital Market Tier With An Extension To May 13, 2024 In Order To Demonstrate Compliance With The Equity Requirement In Listing Rule 5550(b)(1)
Ensysce Biosciences, Inc. (the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that it has received notice fro
BenzingaFeb 27 21:11
Ensysce Receives FDA Guidance on Opioid With Overdose Protection
InvestingFeb 21 21:40
No Data
No Data